The report discusses Merck's aggressive development of pembrolizumab (PD-1) in various cancer treatments, highlighting its leadership in the immuno-oncology space. It includes financial forecasts, investment thesis, valuation, and risks associated with Merck & Co., Inc. The report also provides a detailed financial analysis and performance metrics for Merck.
documents/EFTA00306883.pdf
{}